Live Breaking News & Updates on ஒப்பந்தம் ரோட்ஷோ

Stay updated with breaking news from ஒப்பந்தம் ரோட்ஷோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clin


Search jobs
07-May-2021
Science 37 to Become Publicly Listed via Merger with LifeSci Acquisition II Corp., Powering the Clinical Trial Operating System of the Future
Transaction values Science 37 at an enterprise value of approximately $1.05 billion at closing
Positions Science 37 with a balance sheet of up to $250 million to fund its decentralized trial technology platform, extend into new adjacencies, and power the next generation in clinical research
$80 million via LifeSci Acquisition II Corp., a special purpose acquisition company with no public warrants
$200 million via fully committed and upsized PIPE from leading institutional and strategic investors including Redmile Group; funds and accounts managed by BlackRock; Casdin Capital; dRx Capital (Novartis Pharma AG); LifeSci Venture Partners; Lux Capital; Mubadala Capital, the asset management arm of Mubadala Investment Company; Perceptive Advisors; PPD; P ....

New York , United States , Nina Gill , David Coman , Andrew Mcdonald , Margie Kooman , Diversity In Clinical Research Foundation , Redmile Group , Latham Watkins , Lifesci At Acquisition Ii Corp , Lifesci Acquisition Ii Corp , Mubadala Investment Company , Exchange Commission , Lifesci Capital , Surveyor Capitala Citadel Company , Lifesci Acquisition , Casdin Capital , Novartis Pharma , Lifesci Venture Partners , Lux Capital , Mubadala Capital , Perceptive Advisors , Pura Vida Investments , Samsara Biocapital , Surveyor Capital , Citadel Company ,

Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III


Press release content from Business Wire. The AP news staff was not involved in its creation.
Next-Gen Proteomics Company Nautilus Biotechnology to List on Nasdaq Through Merger with Arya Sciences Acquisition Corp III
February 8, 2021 GMT
SEATTLE & NEW YORK (BUSINESS WIRE) Feb 8, 2021
Nautilus Biotechnology, Inc. (“Nautilus Biotechnology” or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the human proteome, and Arya Sciences Acquisition Corp III (Nasdaq: ARYA) (“Arya III”), a special purpose acquisition company or
SPAC, sponsored by Perceptive Advisors, today announced they have entered into a definitive business combination agreement. Upon closing of the transaction, Arya III will redomicile as a Delaware corporation, be renamed Nautilus Biotechnology, Inc. and its common stock is expected to be listed on Nasdaq under the ticker symbol “NAUT” (the “Combined Company”). ....

New York , United States , San Carlos , Cayman Islands , Wilson Sonsini Goodrich Rosati , Parag Mallick , Konstantin Poukalov , Michael Altman , Adam Stone , Joseph Edelman , Chris Blessington , Sujal Patel , Andreessen Horowitz , Morgan Stanley , Nautilus Biotechnology Inc , Arya Sciences Acquisition Corp , Bain Capital Life Sciences , Madrona Venture Group , Kirkland Ellis , Sciences Acquisition Corp , Exchange Commission , Alyeska Investment Group , Securities Exchange , Goldman Sachs Co , Company Or Nautilus Biotechnology , Perceptive Advisors ,